Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Jiecheng Medical Technology

    • Home
    • Jiecheng Medical Technology
Company Medical Device

Suzhou Jiecheng Medical Secures FDA BDD for Transvascular Aortic Valve Treatment

Fineline Cube Aug 3, 2023

Suzhou Jiecheng Medical Technology Co., Ltd has announced that it has obtained Breakthrough Devices Designation...

Recent updates

  • Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial
  • J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen
  • Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial
  • FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link
  • Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.